• FDA Approves Retacrit drugs
    May 17, 2018
    The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease
PharmaSources Customer Service